Innovative clinical trials that enhance the understanding of cardiovascular disease and improve the care of patients.

Since its inception in 1984, the TIMI Study Group has been an Academic Research Organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease. We have led a wide array of trials, from phase I to phase IV, enrolling from less than 30 to more than 26,000 subjects, and with both industry and NIH support. Trials have been conducted in over 50 countries and at more than 5000 separate sites.

We investigate a broad array of therapeutic interventions in individuals across the spectrum of cardiovascular disease, ranging from prevention in those with risk factors, to emergent interventions in those with acute manifestations of disease. In addition, we have used our large database of clinical findings, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors.

By leading large-scale, international, randomized controlled trials of novel therapeutics and performing sophisticated analyses, we have been privileged to help shape the very practice of cardiovascular medicine for over a quarter of a century.


Academic Trial Leadership

TIMI Study Group investigators provide leadership for clinical trial design, execution, and analysis

Global Trial Operations

Global Trial Management, Biostatistics, Clinical Events Committee, Safety Desk, Medical Hotline

Core Labs

Biomarkers, Proteomics, Metabolomics, Genomics, ECG


Practice-changing contributions to the medical literature

Current and Recent Trials

Recent News and Publications

10/21/2015 - New Publication: Bonaca et al.  Ischaemic risk and efficacy of ticagrelor in relation to time from p2y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from pegasus-timi 54. MORE

9/24/205 - New Publication: Bonaca et al. Long-term use of ticagrelor in patients with prior myocardial infarction. MORE

9/5/2015 - New Publicaton: Bohula et al. Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack. MORE

8/31/2015 - ESC 2015:  PEGASUS-TIMI 54 renal analysis slides 

6/3/2015 - New Publication: Cannon et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. MORE

5/30/2015 - New Publication: O'Donoghue et al. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. MORE

4/28/2015 - OSLER CV Outcomes Paper in NEJM recommended on F1000Prime MORE

4/28/2015 - VIDEO: PCSK9 Inhibitors: What to Know if They Come to Market MORE

03/24/2015 - VIDEO: New IMPROVE-IT analyses reinforce benefits of greater cholesterol reduction MORE

 More News